224 related articles for article (PubMed ID: 16105096)
1. Anti-tumor antibodies in ovarian cancer.
Luborsky JL; Barua A; Shatavi SV; Kebede T; Abramowicz J; Rotmensch J
Am J Reprod Immunol; 2005 Aug; 54(2):55-62. PubMed ID: 16105096
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer.
Barua A; Bradaric MJ; Kebede T; Espionosa S; Edassery SL; Bitterman P; Rotmensch J; Luborsky JL
Am J Reprod Immunol; 2007 Apr; 57(4):243-9. PubMed ID: 17362385
[TBL] [Abstract][Full Text] [Related]
3. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection.
Erkanli A; Taylor DD; Dean D; Eksir F; Egger D; Geyer J; Nelson BH; Stone B; Fritsche HA; Roden RB
Cancer Res; 2006 Feb; 66(3):1792-8. PubMed ID: 16452240
[TBL] [Abstract][Full Text] [Related]
4. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
5. Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients.
Chinni SR; Falchetto R; Gercel-Taylor C; Shabanowitz J; Hunt DF; Taylor DD
Clin Cancer Res; 1997 Sep; 3(9):1557-64. PubMed ID: 9815843
[TBL] [Abstract][Full Text] [Related]
6. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Genazzani AR
Anticancer Res; 1998; 18(5B):3763-5. PubMed ID: 9854491
[TBL] [Abstract][Full Text] [Related]
7. Detection of malignant ovarian neoplasms: a review of the literature. III. Immunological detection and ovarian cancer-associated antigens.
Smith LH; Oi RH
Obstet Gynecol Surv; 1984 Jun; 39(6):346-60. PubMed ID: 6203071
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers for ovarian cancer.
Bhattacharya M; Barlow JJ
Int Adv Surg Oncol; 1979; 2():155-76. PubMed ID: 95453
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention.
Rodríguez-Burford C; Barnes MN; Berry W; Partridge EE; Grizzle WE
Gynecol Oncol; 2001 Jun; 81(3):373-9. PubMed ID: 11371125
[TBL] [Abstract][Full Text] [Related]
10. Characterization of humoral responses of ovarian cancer patients: antibody subclasses and antigenic components.
Taylor DD; Atay S; Metzinger DS; Gercel-Taylor C
Gynecol Oncol; 2010 Feb; 116(2):213-21. PubMed ID: 19945743
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
[TBL] [Abstract][Full Text] [Related]
12. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer.
Cramer DW; Titus-Ernstoff L; McKolanis JR; Welch WR; Vitonis AF; Berkowitz RS; Finn OJ
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1125-31. PubMed ID: 15894662
[TBL] [Abstract][Full Text] [Related]
13. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.
Ayyoub M; Souleimanian NE; Godefroy E; Scotto L; Hesdorffer CS; Old LJ; Valmori D
Clin Immunol; 2006; 118(2-3):188-94. PubMed ID: 16368270
[TBL] [Abstract][Full Text] [Related]
14. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
[TBL] [Abstract][Full Text] [Related]
15. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
[TBL] [Abstract][Full Text] [Related]
16. Presence of aberrant tumor-reactive immunoglobulins in the circulation of patients with ovarian cancer.
Gerçel-Taylor C; Bazzett LB; Taylor DD
Gynecol Oncol; 2001 Apr; 81(1):71-6. PubMed ID: 11277653
[TBL] [Abstract][Full Text] [Related]
17. [Characterization of two antigens OC41 D and OC41 E associated with ovarian carcinoma].
Cui H
Zhonghua Fu Chan Ke Za Zhi; 1993 May; 28(5):284-6, 314-5. PubMed ID: 8243148
[TBL] [Abstract][Full Text] [Related]
18. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.
Valmori D; Souleimanian NE; Hesdorffer CS; Ritter G; Old LJ; Ayyoub M
Clin Immunol; 2005 Oct; 117(1):24-30. PubMed ID: 15994128
[TBL] [Abstract][Full Text] [Related]
19. [Serological analysis of antibodies by anti-idiotypic monoclonal antibody 6B11 against ovarian carcinoma].
Feng J; Lü J; Qian H
Zhonghua Fu Chan Ke Za Zhi; 1996 Aug; 31(8):493-5. PubMed ID: 9275445
[TBL] [Abstract][Full Text] [Related]
20. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
Gagnon A; Kim JH; Schorge JO; Ye B; Liu B; Hasselblatt K; Welch WR; Bandera CA; Mok SC
Clin Cancer Res; 2008 Feb; 14(3):764-71. PubMed ID: 18245537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
